Manufacturers are under pressure to increase production of COVID-19 vaccines as infections from the pandemic approach 110 million people.
BioNTech has signed two new deals with manufacturers to produce lipids at scale, while Moderna's supplier told Reuters it has recently doubled its monthly production of the key ingredients.
Indian health officials say they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in its citizens whose genetic makeup can be different from people in Western nations.
MIG said on Thursday that investors in its funds would now receive 340 million euros from the sale of an unspecified stake in BioNTech, following a payout of 260 million euros last year.
BioNTech now has a market capitalisation of around $28.4 billion, more than eight times its valuation of $3.4 billion.
The FHI said there had been few participants above the age of 65 in the trial conducted by AstraZeneca, meaning there was a lack of documentation as to the effect of the vaccine on older age groups.
Pfizer said it expects there could be a long-lasting need for COVID-19 vaccines, to combat new virus variants that emerge and to "boost" peoples' waning immune responses.
The Pfizer vaccine is produced in Belgium and the European Commission said on Friday it had agreed a plan to control exports of vaccines from the European Union, including to Britain.
With the assurances of both the EU and Belgian Ambassadors, the COVID-19 immunisation plan is expected to proceed according to plan.
The document, which was prepared for a virtual meeting of Chancellor Angela Merkel with the 16 state premiers and representatives of pharmaceutical companies and the European Union later on Monday.
"BioNTech/Pfizer will deliver 75 million of additional doses in the second quarter of the year - and up to 600 millions in total in 2021," von der Leyen wrote on Twitter.
President Joe Biden has pledged to have 100 million people vaccinated within his first 100 days -- but the rollout began slowly under former President Donald Trump.